Publication | Closed Access

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial

OncologyFirst Interim ResultsBevacizumab Biosimilar Ibi305Clinical TrialsPathologyBronchial NeoplasmImmune Checkpoint InhibitorCancer TreatmentMedicineRadiation OncologyLung CancerPhase 3Health Sciences